Great sum up.
The "inherent nonsense" in this stock is ear deafening.
I can fully understand impatience and a lust for cashing in. Not least for those who have been long in the game.
I can fully understand managements decisions for going quiet for so long, while working towards a publication. Considering a decade of harassment and diverting efforts, time and money to deal with fraudulent lawsuits just to try to support SP on a daily basis.
Instead we have proof after proof for progress on anything from patents, IP, certifications, similarity tests manual vs. Flaskworks where we soon will get a certification and now we can even scale and support commercialization for 12.000 patients a year, something all other immunology treatments can only dream of.
We have all the proof that things are happening and progressing towards approval and organisations and oncologists drooling about the efficacy and no side effects, while the combo results look to be even MUCH more efficient, making DCVax-L the most sought out agent for any company with a PD1-inhibiitor.
We now have TLD no matter if we have it or not. We know endpoints succeeded, we just need the details.
There's a lot of forces out now that works incessantly to sow hate against management. Their arguments against DCvax-L not being ATL-DC, endpoint being changed while unblinded etc, has been effectively "killed". So the can is being kicked down a street, that is nearing its end.
Pure desperation, so were back at instigating pitchforks and torches against management, talking about "$0.375" is coming from people who held while at $1.90 and still claims to be holding. And new created user accounts are coming in dozens to show their anxiety and telling us about how long they have been invested.
The fud is beyond appalling.
News 
Market Data 
Discover 
AI
